These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 18347402)

  • 1. [Two cases of severe myelosuppression from amrubicin in previously-treated small cell lung cancer].
    Suzuki H; Sasada S; Matsuda Y; Otani Y; Morishita N; Kobayashi M; Okamoto N; Hirashima T; Matsui K; Kawase I
    Gan To Kagaku Ryoho; 2008 Mar; 35(3):491-3. PubMed ID: 18347402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Our clinical experiences of amrubicin hydrochloride monotherapy in extensive-disease small cell lung cancer].
    Kawakami M; Ohno S; Tsujita A; Hosono T; Kobayashi A; Yamasawa H; Bando M; Sugiyama Y
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):273-6. PubMed ID: 18281764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
    Inoue A; Sugawara S; Yamazaki K; Maemondo M; Suzuki T; Gomi K; Takanashi S; Inoue C; Inage M; Yokouchi H; Watanabe H; Tsukamoto T; Saijo Y; Ishimoto O; Hommura F; Nukiwa T
    J Clin Oncol; 2008 Nov; 26(33):5401-6. PubMed ID: 18854562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amrubicin at a lower-dose with routine prophylactic use of granulocyte-colony stimulating factor for relapsed small-cell lung cancer.
    Hata A; Katakami N; Fujita S; Kaji R; Nanjo S; Otsuka K; Kida Y; Higashi Y; Tachikawa R; Hayashi M; Nishimura T; Tomii K
    Lung Cancer; 2011 May; 72(2):224-8. PubMed ID: 20828862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of relapsed small-cell lung cancer successfully treated by administration of amrubicin].
    Mori H; Tanaka H
    Nihon Kokyuki Gakkai Zasshi; 2007 Dec; 45(12):967-70. PubMed ID: 18186244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term amrubicin chemotherapy for small-cell lung cancer.
    Higashiguchi M; Suzuki H; Hirashima T; Kobayashi M; Goya S; Okamoto N; Matsuura Y; Tamiya M; Morishita N; Kawase I
    Anticancer Res; 2012 Apr; 32(4):1423-7. PubMed ID: 22493380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of amrubicin for non-small cell lung cancer after failure of two or more prior chemotherapy regimens.
    Igawa S; Takahashi T; Nakamura Y; Tsuya A; Ono A; Shukuya T; Murakami H; Endo M; Yamamoto N
    Anticancer Res; 2008; 28(6B):3855-8. PubMed ID: 19192640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of adverse events of amrubicin hydrochloride for pretreated lung cancer patients].
    Takase M; Maruoka H; Maeda R; Shibata K
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1789-92. PubMed ID: 18030011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case of small cell lung cancer under hemodialysis with chronic renal failure treated with amrubicin while measuring blood concentration of the drug].
    Goto N; Shibuya H; Har K; Hisada T
    Nihon Kokyuki Gakkai Zasshi; 2007 Apr; 45(4):337-43. PubMed ID: 17491313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amrubicin monotherapy for elderly patients with previously treated lung cancer.
    Nakao M; Oguri T; Suzuki T; Kunii E; Tomita Y; Iwashima Y; Miyazaki M; Maeno K; Sato S; Ueda R
    Intern Med; 2010; 49(17):1857-62. PubMed ID: 20823645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer.
    Watanabe H; Ikesue H; Oshiro M; Nagata K; Mishima K; Takada A; Suetsugu K; Sueyasu M; Egashira N; Harada T; Takayama K; Nakanishi Y; Oishi R
    Chemotherapy; 2012; 58(6):419-25. PubMed ID: 23295219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.
    Okamoto I; Hamada A; Matsunaga Y; Sasaki J; Fujii S; Uramoto H; Yamagata H; Mori I; Kishi H; Semba H; Saito H
    Cancer Chemother Pharmacol; 2006 Feb; 57(3):282-8. PubMed ID: 16028099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Small cell lung cancer: value of G-CSF].
    Trillet V
    Pathol Biol (Paris); 1993 Jan; 41(1):46. PubMed ID: 7686284
    [No Abstract]   [Full Text] [Related]  

  • 14. Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung.
    Yoshida H; Sekine I; Tsuta K; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Tamura T
    Jpn J Clin Oncol; 2011 Jul; 41(7):897-901. PubMed ID: 21636606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender difference in hematological toxicity among lung cancer patients receiving amrubicin monotherapy.
    Makihara RA; Makino Y; Yamamoto N; Yokote N; Nokihara H; Sekine I; Ohe Y; Tamura T; Yamamoto H
    Jpn J Clin Oncol; 2012 Dec; 42(12):1187-91. PubMed ID: 23081985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.
    Asao T; Nokihara H; Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Yamamoto N; Sekine I; Kunitoh H; Fujiwara Y; Ohe Y
    Jpn J Clin Oncol; 2015 Oct; 45(10):941-6. PubMed ID: 26232449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetic study of amrubicin in a case of small lung cancer on hemodialysis].
    Ohsawa M; Demizu M; Chihara S; Ueda H; Igarashi T; Tomiyama N; Nakashima Y; Hosoi K; Min K
    Gan To Kagaku Ryoho; 2009 Aug; 36(8):1311-4. PubMed ID: 19692770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer.
    Makino Y; Yamamoto N; Sato H; Ando R; Goto Y; Tanai C; Asahina H; Nokihara H; Sekine I; Kunitoh H; Ohe Y; Sugiyama E; Yokote N; Tamura T; Yamamoto H
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):861-9. PubMed ID: 22042514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABCB1 polymorphism as a predictive biomarker for amrubicin-induced neutropenia.
    Takakuwa O; Oguri T; Uemura T; Kunii E; Nakao M; Hijikata H; Kawaguchi Y; Ohkubo H; Takemura M; Maeno K; Niimi A
    Anticancer Res; 2014 Jul; 34(7):3517-22. PubMed ID: 24982363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
    Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
    J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.